ARA-290 is a synthetic peptide derived from erythropoietin (EPO), a hormone traditionally associated with red blood cell production.

The Ekosiisen Impact Project, an initiative under Asempa FM’s flagship current affairs programme Ekosiisen, has intensified its support for renal patients across Ghana, following a distress call from ...

The global erythropoietin drugs market was valued at approximately USD 6.87 billion in 2022 and is projected to grow at a healthy growth rate of around 1.5% during the forecast period from 2023 to ...

Low levels of erythropoietin (EPO), a substance in the blood that stimulates red blood cell production in preterm infants, provide a rationale for the use of EPO to prevent or treat anaemia. A total ...

In contrast to the recently reported studies of Epo in patients hospitalized in intensive care units focusing on those with trauma, [60] our study was designed to minimize the risk of Epo-induced ...

Erythropoietin reduces infarct size, but it also carries some potentially adverse affects. How can you effectively administer this drug to improve the prognosis of heart disease patients?

We hypothesized that cord blood erythropoietin (EPO), a marker of fetal hypoxia, relates to gestational factors and not solely those associated with delivery. We investigated the association ...

Background— Erythropoietin (Epo) receptors (EpoRs) are expressed in the heart. We have recently demonstrated that the endogenous Epo-EpoR system plays an important protective role in myocardial ische ...

Inappropriately low erythropoietin level is an important cause of early anemia in patients with diabetes mellitus 14 (the multiple functions of erythropoietin are summarized in Box 2).

However, the primary cause of anemia is erythropoietin (EPO) deficiency resulting from diminished production in the kidneys (3, 4). The correction of anemia in patients with CKD requires the use of ...